SecBot SecBot

LEXX

Lexaria Bioscience Corp.
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001348362 Biotech & Drug Discovery
$2.85 −0.23 (−7.47%)
Oct 26 4:00 PM ET · prev $3.08
Market cap
$6.3M
Nano cap
Median target
$82.50
+2795% · range $82.50–82.50
1 year
−81.0%
from $15.00 · Oct 27
30 days
−11.6%
from $3.22
52-week range
$2.60–20.10
−86% from high · low Oct 19
Avg volume 20D
62.1K
Oct 9 spike 198.4K
Short interest
274.5K
≈13.0% of shares · +53.4%
Days to cover
4.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 3 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 4/5
Strongest BEARISH The SEC declared effective Lexaria Bioscience Corp.'s S-3 shelf registration (File No. 333-299257) on…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 5 added (0 new), 2 trimmed or exited.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.900 → −$0.900 over 90 days.

  • Short sellersBUILDING

    Short interest +53.4% to 274.5K shares. 4.0 days to cover, ≈13.0% of shares.

  • TrendDOWNTREND

    52% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 5.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCADD298,436$167.1K
CITADEL ADVISORS LLCDOUBLED156,945$87.9K
TORONTO DOMINION BANKTRIM100,013$56.1K
HRT FINANCIAL LPDOUBLED65,049$36.0K
NORTHERN TRUST CORPDOUBLED39,825$22.3K
Vontobel Holding Ltd.TRIM15,189$8.5K
OSAIC HOLDINGS, INC.DOUBLED2,195$1.2K
GEODE CAPITAL MANAGEMENT, LLCADD294,157$229.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Dec 2025
12-month targets · 1 analysts

Price is below the lowest target. Median implies +2795%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Dec 26, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 29, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 1, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jan 24, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Dec 2, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Nov 25, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Mar 17, 2026
BUNKA CHRISTOPHER
Director
GIFT100,000 sh

Earnings setup

Estimates
−$0.90
EPS estimate, this quarter
0%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.90-$0.90–-$0.90+0.0%$0.00
Next Q———$0.00
Current FY-$4.05-$4.05–-$4.05-3.8%$20.0K
Next FY-$4.65-$4.65–-$4.65+0.0%$1.4M
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Aug 17, 2026
Listing
Listing Status: LEXX — Normal (was Deficient)
Lexaria Bioscience Corp. - Common Stock | Nasdaq Financial Status Indicator D → N
Aug 3, 2026
Trading halt
Halt Resumed: LEXX — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-03T13:59:23.000Z | Resumed 2026-08-03T14:04:23.000Z
Aug 3, 2026
Trading halt
Trading Halt: LEXX — LUDP (Volatility Trading Pause)
Lexaria Bioscience Corp. Cm St | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Aug 3, 2026
Trading halt
Halt Resumed: LEXX — trading resumed after T3 (News and Resumption Times)
Halted 2026-07-31T23:50:00.000Z | Resumed 2026-08-03T13:00:00.000Z
Jul 31, 2026
Trading halt
Trading Halt: LEXX — T1 (News Pending)
Lexaria Bioscience Corp. Cm St | Market: NASDAQ | Code: T1 — News Pending

Short side

FINRA· Sep 30, 2026
274,542
shares short
+53.4%
vs prior settlement
4.0
days to cover
≈13.0%
of shares outstanding
Trading halts
Aug 3, 2026Volatility PauseResumed
Jul 31, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
The SEC declared effective Lexaria Bioscience Corp.'s S-3 shelf registration (File No. 333-299257) on October 13…
EFFECT — Impact 5/10
Oct 1, 2026 SEC
Lexaria Bioscience Corp. filed an S-3 registration statement to register up to 923,827 shares of common stock for…
S-3 — Impact 5/10
Sep 1, 2026 SEC
Lexaria Bioscience Corp. received an AUD$3,666,611.98 (USD$2.6M) R&D tax credit from the Australian Tax Office for its…
8-K — Impact 6/10
Aug 17, 2026 Listing status
Listing Status: LEXX — Normal (was Deficient)
Lexaria Bioscience Corp. - Common Stock | Nasdaq Financial Status Indicator D → N
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
298,436 shares ($167.1K)
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
156,945 shares ($87.9K)
Mar 17, 2026 Insider
BUNKA CHRISTOPHER gifted 100,000 shares
Director
Reddit
Recent posts
r/pennystocks Bullish 21d ago
$LEXX: Trading at Negative Enterprise Value Ahead of a Massive GLP-1 Catalyst Ladder 🚨🔥 📈
0 upvotes · 0 comments
All social signals and their track records

SecBot reports

5 filings · 1 bullish · 3 bearish · 1 neutral
All LEXX filing & press-release reports (5)